Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA

The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D. The facility will create more than 1,900 jobs and support the production of next-generation metabolic medicines, including treatments for obesity These investments underscore Roche’s commitment to innovative manufacturing, designed to bring life-changing treatments to patients faster Basel, 25 August 2025 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today broke ground on ...